“Real-world data revealed a strong association between receipt of neutralizing monoclonal antibodies (mAbs) and reduced hospitalization and death among COVID-19 outpatients across multiple pandemic phases and provided valuable data to inform scarce resource allocation decisions,” Matthew K. Wynia, director of the Center for Bioethics and Humanities at University of Colorado, Anschutz Medical Campus, and colleagues wrote.